Literature DB >> 12043884

Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome.

D Erkan1, H W Zhang, R C Shriky, J T Merrill.   

Abstract

The antiphospholipid syndrome (APS) is a thrombotic disorder leading to spontaneous abortions, venous thromboses, myocardial infarctions and strokes. Although the syndrome is associated with characteristic autoantibodies, these tests have poor predictive value for thrombosis. The aim of the study was to determine whether the combined presence of two types of antiphospholipid antibodies can be associated with a high-risk subset of thrombosis-prone patients. One hundred and thirty-four sera from a lupus clinic were tested for antibodies to beta2-glycoprotein I (beta2GPI), protein S and prothrombin. In a group of 29 patients for whom plasma was available, free (functional) protein S levels were also measured. Autoantibodies to beta2GPI and protein S are associated with each other. Dual reactivity to beta2GPI and protein S correlates with increased history of thrombotic events (69% of doubly reactive patients) when compared to either type of autoantibody alone (37% of patients with only anti-beta2GPI and 38% with only anti-protein S, P=0.04 and P=0.01, respectively) or neither reactivity (37%). Among 29 patients tested for free (functional, anticoagulant) protein S levels, the lowest levels were found in patients with antibodies to beta2GPI and/or protein S, and all four patients with a history of thrombosis had below-normal free protein S levels. These associations were not found with antiprothrombin antibodies. In conclusion dual autoantibodies to beta2GPI and protein S are associated with increased history of thrombosis in the antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12043884     DOI: 10.1191/0961203302lu178oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  18 in total

Review 1.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

Review 3.  Diagnosis of the antiphospholipid syndrome: how far to go?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

4.  Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase.

Authors:  Changyi Chen; Dan Liao; Jing Wang; Zhengdong Liang; Qizhi Yao
Journal:  Thromb Res       Date:  2013-11-16       Impact factor: 3.944

Review 5.  Antiphospholipid syndrome: genetic review.

Authors:  Bahram Namjou
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

6.  Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.

Authors:  Wei-Shiang Lin; Pei-Chih Chen; Cheng-De Yang; EunJung Cho; Bevra H Hahn; Jennifer Grossman; Kwan-Ki Hwang; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2007-05

7.  IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.

Authors:  Chunya Bu; Zhihuan Li; Chune Zhang; Lei Gao; Guoping Cai
Journal:  Clin Rheumatol       Date:  2007-07-24       Impact factor: 2.980

8.  Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.

Authors:  John G Hanly; Murray B Urowitz; Li Su; Caroline Gordon; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Daniel J Wallace; Ann E Clarke; Em Ginzler; Joan T Merrill; David A Isenberg; Anisur Rahman; M Petri; Paul R Fortin; Dd Gladman; Ian N Bruce; Kristjan Steinsson; Ma Dooley; Munther A Khamashta; Graciela S Alarcón; Barri J Fessler; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Rf van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Ann Rheum Dis       Date:  2012-04-04       Impact factor: 19.103

9.  Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S-C Bae; C Gordon; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; D J Wallace; P R Fortin; D Gladman; J Romero-Diaz; J Romero-Dirz; J Sanchez-Guerrero; M A Dooley; I Bruce; K Steinsson; M Khamashta; S Manzi; R Ramsey-Goldman; G Sturfelt; O Nived; R van Vollenhoven; M Ramos-Casals; C Aranow; M Mackay; K Kalunian; G S Alarcón; B J Fessler; G Ruiz-Irastorza; M Petri; S Lim; D Kamen; C Peschken; V Farewell; K Thompson; C Theriault; J T Merrill
Journal:  Ann Rheum Dis       Date:  2011-10       Impact factor: 19.103

10.  Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Qiuju Li; Li Su; Murray B Urowitz; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad A Zoma; Susan Manzi; Ola Nived; Andreas Jonsen; Munther A Khamashta; Graciela S Alarcón; Elisabet Svenungsson; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; Manuel Ramos-Casals; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2019-11-28       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.